PCA PCAS SA

PCAS Combined General Meeting: Due to COVID 19 containment measures, shareholders are invited to vote by mail

PCAS Combined General Meeting: Due to COVID 19 containment measures, shareholders are invited to vote by mail



Ecully, April 20, 2020

PCAS Combined General Meeting: Due to COVID 19 containment measures, shareholders are invited to vote by mail

The PCAS board of Directors, meeting today, decided to hold the Annual General Meeting behind closed doors at PCAS headquarters in Ecully on May 12, 2020. In compliance with the instructions of the government and the health authorities aimed at fight against the spread of the coronavirus by limiting meetings as much as possible, and, in accordance with the provisions of ordinance n ° 2020-321 dated March 25, 2020, PCAS invites those of its shareholders who had planned to attend its general meeting of May 12, 2020 to vote by mail or to give a proxy to the Chairman of the Meeting. In this context, PCAS wishes to inform its shareholders of the following exceptional provisions:  

1 - Postal voting procedures

PCAS recommends that its shareholders vote by post by sending their ballot before May 7, 2020 3:00 p.m. (Paris time) and in the manner described in the notice of meeting published in the Bulletin des Annonces Légales Obligatoires on April 24, 2020 and available on the Company's website in the “Investors” section.

2 - Questions from shareholders

During the meeting, it will not be possible to ask questions or to propose draft amendments or new resolutions.

Shareholders are invited to ask their questions in writing by sending them without delay, and before May 6, 2020 at the latest, by email to the following email address : . The Company will respond to them during the Meeting and in the minutes of its Meeting, which will be published on its website in the "Investors" section. To be taken into account, these questions must imperatively be accompanied by an account registration certificate.

3 - Online distribution  

On May 12, 2020, from 2 p.m. (Paris time), a presentation by the Chairman and Chief Executive Officer of the Company of the activity of the Company during the year ended will be webcast on the website of the Company It will be followed by the results of the votes on the resolutions submitted to the vote of the Meeting, on the basis of the postal votes and the powers of the President received by CIC at the email address until May 7, 2020 inclusive.



All useful information on this General Meeting will also be published on the Company's website in the “Investors” section. Shareholders are invited to consult this section regularly.





NEXT FINANCIAL DISCLOSURE:

2020 Annual General Meeting in Ecully behind closed doors at 2 pm on May 12, 2020

ABOUT PCAS

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 10% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €200.9 million in 2019 and employs close to 1 100 people in six countries.

To find out more about PCAS:



PCASNewcap
 



Pierre Luzeau / Eric Moissenot
 



Emmanuel Huynh / Louis-Victor Delouvrier

Financial communication and investor relations
Tél. : 00



Tél. : 53

Attachment

EN
20/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PCAS SA

 PRESS RELEASE

PCAS : Réalisation de l’augmentation de capital de PCAS d’un montant d...

PCAS : Réalisation de l’augmentation de capital de PCAS d’un montant de 200 millions d’euros, après retrait obligatoire des titres de la société Ecully, le 18 décembre 2023 Réalisation de l’augmentation de capital de PCAS d’un montant de 200 millions d’euros, après retrait obligatoire des titres de la société A la suite du retrait obligatoire visant les titres de PCAS intervenu le 8 décembre 2023, le conseil d’administration de PCAS a décidé, comme annoncé dans le cadre de l’offre publique d’achat simplifiée initiée par Seqens, une augmentation de capital de PCAS d’un montant tota...

 PRESS RELEASE

PCAS - Mise à disposition de la note en réponse et des informations re...

PCAS - Mise à disposition de la note en réponse et des informations relatives aux caractéristiques, notamment juridiques, financières et comptables de la société dans le cadre de l’OPAS COMMUNIQUE DU 2 NOVEMBRE 2023 RELATIF A LA MISE A DISPOSITION DE LA NOTE EN REPONSE ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LA SOCIETE PCAS DANS LE CADRE DE L’OFFRE PUBLIQUE D’ACHAT SIMPLIFIEE VISANT LES ACTIONS DE LA SOCIETE SEQENS  AVIS IMPORTANTConformément aux dispositions de l’article L. 433-4 II du Code monétaire et financier et de...

 PRESS RELEASE

PCAS: Net Sales as of September 30, 2023

PCAS: Net Sales as of September 30, 2023 Ecully, October 24, 2023 NET SALES AS OF SEPTEMBER 30, 2023 PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of September 30, 2023. The PCAS Group has generated consolidated net sales of €151.9 million as of September 30, 2023, a 2,7% decrease compared to the same period during the previous financial year (-2.8% at constant exchange rates). In millions of euros 2023 9 months 2022 9 months % change 20...

 PRESS RELEASE

PCAS : chiffre d’affaires au 30 septembre 2023

PCAS : chiffre d’affaires au 30 septembre 2023 Ecully, le 24 octobre 2023 CHIFFRE D’AFFAIRES AU 30 SEPTEMBRE 2023   PCAS (Euronext Paris : PCA), spécialiste du développement et de la production de molécules complexes pour les Sciences de la Vie et les Technologies innovantes, annonce la publication de son chiffre d’affaires consolidé au 30 septembre 2023. Le chiffre d’affaires consolidé du Groupe PCAS s’établit à 151,9 M€ au 30 septembre 2023, en baisse de 2,7% par rapport à la même période de l’exercice précédent (-2,8% à taux de change constant). en millions d'euros 2023 9 mois 2022 9...

 PRESS RELEASE

PCAS : COMMUNIQUÉ DU 12 OCTOBRE 2023 RELATIF AU DÉPÔT D’UN PROJET DE N...

PCAS : COMMUNIQUÉ DU 12 OCTOBRE 2023 RELATIF AU DÉPÔT D’UN PROJET DE NOTE ÉTABLI PAR LA SOCIÉTÉ PCAS EN RÉPONSE AU PROJET D’OFFRE PUBLIQUE D’ACHAT SIMPLIFIÉE VISANT LES ACTIONS DE LA SOCIÉTÉ PCAS INITIÉE PAR LA SOCIÉTÉ SEQENS COMMUNIQUÉ DU 12 OCTOBRE 2023 RELATIF AU DÉPÔT D’UN PROJET DE NOTE ÉTABLI PAR LA SOCIÉTÉ PCAS EN RÉPONSE AU PROJET D’OFFRE PUBLIQUE D’ACHAT SIMPLIFIÉE VISANT LES ACTIONS DE LA SOCIÉTÉ PCAS INITIÉE PAR LA SOCIÉTÉ SEQENS Le présent communiqué a été établi et est diffusé le 12 octobre 2023 en application des dispositions de l’article 231-26 du règlement général de l’...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch